kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human TRAILR1 /DR4 /TNFRSF10A Protein, C-Fc Tag, 100µg  

Recombinant Human TRAILR1 /DR4 /TNFRSF10A Protein, C-Fc Tag, 100µg

Recombinant Human TRAILR1 /DR4 /TNFRSF10A Protein, Ala 24 - Asn 239, expressed from human 293 cells (HEK293), Fc Tag

recombinant , human protein, TNFRSF10A, TRAIL-R1, CD261, APO2, DR4

More details


Availability: within 7 days

338,00 €

Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) also known as TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), Death receptor 4 (DR4), CD261 and APO2, which belongs to TNF superfamily. TRAILR1 / TNFRSF10A contains 1 death domain and 3 TNFR-Cys repeats. TNFRSF10A / DR4 is widely expressed and high levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells. APO2 / TNFRSF10A is receptor for the cytotoxic ligand TNFSF10 / TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAILR-1 / DR4 / CD261 promotes the activation of NF-kappa-B.

Recombinant Human TRAIL R1, Fc Tag (TR1-H5254) is expressed from human 293 cells (HEK293). It contains AA Ala 24 - Asn 239 (Accession # NP_003835).
Predicted N-terminus: Ala 24

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 49.0 kDa. The protein migrates as 45-50 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Less than 1.0 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Please refer to product data sheet:

Clinical and Translational Updates

(1) "(4-Picolylamino)-17β-Estradiol derivative and analogues induce apoptosis with death receptor trail R2/DR5 in MCF-7"
Yin, Sun, Sheng et al
Chem Biol Interact (2023) 369, 110286
(2)"Trailing TRAIL resistance in human breast adenocarcinoma cells with Trichostatin A and Zebularine"
Wong, Fang, Loh et al
Anticancer Agents Med Chem (2022)
(3) "Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?"
Curry, Morris, Barton et al
Pharmacogenomics J (2022)
Showing 1-3 of 573 papers.